Actively Recruiting
Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-01-16
256
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire, Amiens
Lead Sponsor
U
University Hospital, Rouen
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying antibiotic use in elderly patients hospitalized with viral respiratory infections such as influenza, parainfluenza, RSV, and SARS-CoV-2. These infections carry a high risk of mortality, especially when complicated by bacterial co-infections, which significantly increase death risk. The study aims to provide strong evidence on whether stopping antibiotics early in viral infections is safe or potentially harmful, addressing the common overuse of antibiotics in these cases. Participants are assigned to one of two groups: one where antibiotics are stopped early based on viral or negative test results, and a standard care group where antibiotics are given as usual. The standard antibiotics include Amoxicillin-clavulanic acid, Ceftriaxone, Piperacillin-Tazobactam, or Pristinamycin, each administered for seven days with specified doses. The study begins with hospitalization and microbiological testing within 48 hours and monitors patients during their hospital stay. Throughout the study, researchers track the number of days patients go without antibiotics over 30 days, antibiotic side effects, mortality at 30 and 180 days, and length of hospital stay. Patient consent is required, and evaluations include clinical signs, imaging tests, and microbiological samples. The total participation may extend up to six months for mortality follow-up, ensuring comprehensive safety and outcome monitoring.
CONDITIONS
Brief Title
Early Discontinuation of Antibiotic Therapy in Elderly Patients Hospitalized for a Viral Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 65 years or older
- Affiliated to a social security scheme
- Hospitalized for a lower respiratory infection defined by at least 2 of the following signs: fever over 38°C, high or low white blood cell count (≥12000 or ≤4000), purulent secretions, or abnormal lung sounds indicating damage
- Presence of a pulmonary image on X-ray, CT scan, or ultrasound
- Microbiological diagnostic sample taken within 48 hours of admission
- Patient or representative provides informed consent
You will not qualify if you...
- Hospitalization planned for less than 48 hours or transfer to another center within 7 days
- Patient in septic shock
- Febrile aplasia
- No microbiological sampling within 48 hours after admission
- Moribund patient or death expected within one week
- Proven inhalation injury by endoscopy or eyewitness
- Presence of purulent pleurisy, lung abscess, or other bacterial infection requiring antibiotics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 days
Participants receive antibiotic therapy or undergo early discontinuation of antibiotics based on viral or negative test results.
Daily visits during antibiotic therapy
Duration - Up to 6 months
Participants are monitored for side effects, mortality, and length of hospitalization after treatment ends.
Visits at 1 month and 6 months post-treatment
Trial Site Locations
Total: 1 location
1
CHRU Amiens
Amiens, France, 80054
Actively Recruiting
Research Team
J
Jean-Philippe LANOIX, Pr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here